UPDATE: Positive results for Jardiance in CV risk reduction in diabetics at risk of stroke

German family-owned Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) yesterday announced positive top-line results from EMPA-REG OUTCOME with their jointly developed diabetes drug Jardiance (empagliflozin).

This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. EMPA-REG OUTCOME met its primary endpoint and demonstrated superiority of Jardiance, when added to standard of care, in CV risk reduction. The primary endpoint was defined as time to first occurrence of either CV death, or non-fatal myocardial infarction or non-fatal stroke.

Jardiance is the only glucose-lowering agent to have demonstrated CV risk reduction in a dedicated cardiovascular outcomes trial.